Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADP-ribosylation factor-like protein 3 (ARL3) is a member of the ARF-like family of small GTPases, functioning as a regulatory switch that cycles between inactive GDP-bound and active GTP-bound states[2][3][1]. ARL3 is predominantly involved in the regulation of ciliary trafficking of lipid-modified proteins and is essential for cilium function, photoreceptor development, and maintenance[2][1][4]. It localizes to the centrosome, primary cilium, Golgi apparatus, mitochondria, and endosomes, and can influence processes such as cell division and autophagy regulation[2][3][4]. ARL3 is activated by the guanine exchange factor ARL13B, with cofactors such as BART and ARL2BP facilitating full activation and proper function[1][2]. Dysregulation or mutations in ARL3 cause a spectrum of ciliopathies, including Joubert syndrome, retinal dystrophies (such as cone-rod dystrophy and retinitis pigmentosa), and other multisystem disorders due to defects in ciliary trafficking and photoreceptor degeneration[2]. No direct pharmacological modulators or clinical drugs acting on ARL3 are currently known.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADP-ribosylation factor-like protein 3 (ARL3).